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Abstract 
 
Cross sectional Imaging plays an increasingly important role the diagnosis 
and management of Crohn’s disease. Particular emphasis is placed on MRI 
and Ultrasound as they do not impart ionising radiation. Both modalities have 
reported high sensitivity for disease detection, activity assessment and 
evaluation of extra-luminal complications, and have positive effects on clinical 
decision making. International Guidelines now recommend MRI and 
Ultrasound in the routine management of Crohn’s disease patients. This 
article reviews the current evidence base supporting both modalities with an 
emphasis on the key clinical questions. We describe current protocols, basic 
imaging findings and highlight areas in need of further research.   
Index terms: Crohn’s disease, MR Enterography, Small bowel ultrasound 
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Introduction 
 
Crohn’s disease (CD) is a lifelong condition characterised by recurrent 
gastrointestinal (GI) tract inflammation (1). Prevalence is highest in North 
America and Europe, with 145-199 cases per 100 000, equating to 400-600 
000 sufferers in North America alone (2–4). Most patients with CD present 
when young, with peak incidence between 15-25 years. The total economic 
burden of CD is estimated to be $10.9-15.5 billion in the US and €2.1-16.7 
billion in Europe (3,5). Furthermore, as well as attracting considerable 
morbidity, the age-adjusted mortality risk for CD is around 50% higher than 
that of the general population (2). 
 
The disease has a wide array of intestinal manifestations ranging from 
superficial mucosal ulceration, through to transmural inflammation, 
inflammatory and fibrotic stricturing, sinus, fistulae and abscess formation 
(6,7). Accurate phenotyping and staging of CD is essential for optimal 
management.   An array of medical therapies are available including 
antibiotics, steroids, and immune-modulators such as anti-TNF alpha agents, 
each attracting their own benefits and side-effect profiles. Targeted surgical 
and endoscopic interventions also play an important role (6–9). However CD 
phenotyping is complex and requires accurate delineation of disease 
presence, segmental location, the relative contribution of inflammatory activity 
versus irreversible fibrosis, and the presence of extra-luminal complications.  
Furthermore, CD is also characterized by periods of relapse and remission. 
Thus phenotyping must be repeated at regular intervals. Indeed, annual 
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reassessment is mandated for patients on immune modulators so that 
management is optimised (7,10). The use of cross-sectional imaging to 
diagnose and phenotype CD has risen dramatically in recent years. Whilst it is 
acknowledged that there is a strong supporting literature for the use of CT 
entereography in CD (11,12), given the lifelong nature of the disease and 
patient demographics, an emphasis has been placed on those imaging 
modalities that avoid ionising radiation, notably MRI and ultrasound, this 
review describes the role of these two modalities for management of CD.  
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General role of Imaging in Crohn’s Disease  
 
Diagnosis and staging of CD is challenging and no single diagnostic test that 
achieves this is available (13,14). Instead, diagnosis is based on a 
combination of clinical evaluation and endoscopic, histological, radiological, 
and biochemical investigation (13,14). Such complexity in part reflects the 
relative inaccessibility of the gut to diagnostic interrogation. Endoscopy plays 
a pivotal role in diagnosis and follow up of CD, and is the best tool for luminal 
evaluation. However the terminal ileum  (the most commonly affected bowel 
segment; 75% of patients) (15) may be inaccessible to ileocolonoscopy in up 
to 25% of patients (16,17). Furthermore CD often involves more proximal 
small bowel, unequivocally out of the reach of the colonoscope, and 
endoscopy may also underdiagnose extraluminal complications such as 
fistulae (18,19).  
 
Proximal small bowel evaluation is now possible via video capsule endoscopy 
(VCE)(20).  In a recent 4-way comparison, VCE achieved similar sensitivity for 
active small-bowel CD as CT Enterography (CTE), colonoscopy, and Barium 
Follow-through (BaF) (21). However specificity was low at just 53%, which is 
problematic given the implications of diagnosing CD in an unaffected 
individual. Additionally, VCE risks capsule retention due to stenosis and may 
also localise bowel abnormalities poorly (22). 
 
Validated clinical indices such as the Crohn’s Disease Activity Index (CDAI) 
give some information regarding the level of inflammatory activity but are 
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falling out of favour, as data increasingly reports relatively poor correlation 
with objective markers of biologic activity such as enodsocopy  (23,24) and in 
any event give little insight regarding the anatomical distribution of disease or 
any associated extra-luminal complications (25).  
 
Given the limitations of both endoscopy and clinical scoring systems, imaging 
has assumed a central role in the management of CD. A number of small 
bowel imaging tests are commonly used: barium follow though (BaF), CT 
enterography (CTE), MR Enterography (MRE) and small bowel ultrasound 
(SBUS), all with differing attributes. In the relatively recent past, the most 
frequently employed of these were BaF and CTE - a UK survey in 2010 
reported 90% of radiology departments used BaF routinely and 80% used CT 
to investigate patients with known or suspected CD (26). BaF is long 
established and in widespread use in some parts of the world, although in 
many countries it is rapidly falling out of favor and being replaced by cross 
sectional imaging.  
It has high accuracy for diagnosing mucosal abnormality but is limited in its 
evaluation of mural and extra-mural disease.  CTE has undoubtedly increased 
in popularity following the advent of multidetector-row scanners, affording high 
resolution abdominal scanning in a single breath-hold. It is fast, readily 
available and its clinical utility has been demonstrated in many studies 
(12,27). It is accurate for disease detection and its ability to quantify disease 
activity is comparable to other imaging modalities (28). Unfortunately both 
BaF and especially CTE expose patients to ionising radiation (29).  
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As noted above, CD patients are often young and require repeated imaging 
over the course of their disease. A 2007 audit revealed 15.5% of CD patients 
acquired a cumulative radiation dose resulting in an increased cancer risk of 
7.3%, mainly due to CT (30). Both patients and doctors are increasingly 
aware of these risks and are rightly focusing on limiting radiation exposure. 
New CT technologies such as iterative reconstruction for CTE will 
undoubtedly have a major positive impact on reducing radiation exposure, but 
MRE and SBUS remain the only two truly radiation free techniques in 
common clinical usage (31,32). 
 
The underlying complexity of the disease and array of treatment options 
necessitates that CD is best managed in a multi-disciplinary team 
environment (33). Radiologists must therefore be fully aware of the clinical 
management decisions faced by their gastroenterological and surgical 
colleagues. In the following discussion, particular emphasis is placed on the 
role of MRE and SBUS in addressing some of the most important clinical 
questions that imaging must answer: 
1. Is disease present and, if so, is it predominantly active (and amenable 
to immunosuppressive therapy) or predominantly fibrotic (and better 
suited to endoscopic or surgical intervention)? 
2. Are there associated extra-luminal complications such as abscess or 
fistulae that will need attention? 
3. Has medically treated disease responded adequately to therapy? 
4. To what extent does imaging impact on patient management? 
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MR Enterography 
 
Summary of Technique 
 
MRE combines fast imaging sequences with enteric luminal distension to 
evaluate the bowel and extra luminal tissues(14). Adequate patient 
preparation is vital for high quality MRE. The key to small bowel imaging using 
MRI is luminal distension since collapsed bowel can both hide and mimic 
disease. Distension is achieved via oral administration of large volumes of 
hyperosmolar liquid, which, unlike water, is poorly absorbed and therefore 
remains within the lumen over the course of the examination. Biphasic (ie low 
signal on T1-weighted images and high signal on T2-weighted images) oral 
contrast agents are used most widely and common examples include 
polyethylene glycol, mannitol, and low-density barium. Biphasic agents 
provide excellent contrast between bowel lumen and wall without obscuring 
mural enhancement from intravenous gadolinium. Several ingestion regimes 
are described, but typical volumes in common use range from 1,000–
2,000mls, ingested steadily over the 40-60 min prior to scanning (15,34). A 
variant of MRE, MR enteroclysis uses nasojejunal intubation to infuse enteric 
contrast directly into the lumen. Distension is improved versus MRE, 
particularly in the proximal bowel, but this may not translate into diagnostic 
benefit over simple enterography (35,36). Furthermore MR enteroclysis is 
invasive, less well tolerated by patients than MRE, and necessitates radiation 
exposure for tube placement (35,36). It is therefore usually employed for 
solving specific problems. 
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Recent advances in MRI technology allow rapid acquisition of high-resolution 
images. MRE protocols generally include fast spin echo (FSE) T2-weighted 
sequences (with and without fat saturation), steady state free precession 
gradient echo (SSFP GE) sequences without fat saturation, and unenhanced 
and gadolinium-enhanced T1-weighted sequences. Axial and coronal images 
are acquired: A typical sequence protocol is shown in table1.  
 
Most work on MRE for CD has been performed at 1.5T, but there is increasing 
evidence that 3T platforms can also provide high quality examinations (37,38). 
The multi sequence combination is intended to simultaneously evaluate 
mucosal, mural and peri-mural disease (14).  Additional sequences such as 
“cine” motility and diffusion-weighted imaging (DWI) have an increasingly 
supportive evidence base. Motility imaging can be performed with fast T2-
weighted or SSFP GE cine sequences and captures peristaltic activity. As 
discussed below, impaired motility is a biomarker of CD activity and therefore 
treatment response (39).  Restricted diffusion in affected bowel has been 
associated with underlying biological activity in a number of studies 
(employing a range of reference standards, including endoscopy and surgical 
specimens)(40). For example, Kim et al. performed MRE in 50 patients 
including DWI (b = 900 sec/mm2), followed by ileocolonoscopy within 1-week. 
Segments were classified by the severity of endoscopic findings (deep or 
superficial ulcers, aphthae, erythema, edema only, or no inflammation). MRE 
with DWI was more sensitive for inflammation than MRE alone (83%  versus 
62%; p = 0.001) (41). Qi et al. recruited 36 patients who underwent 3T MRE 
 11 
with DWI (5 b values, 0, 800, 1500, 2000, 2500 sec/mm2) and single/double 
balloon enteroscopy within a week. A b value of 800 sec/mm2 was most 
sensitive for active CD (74.19%). MRE combined with DWI was more 
sensitive (94%), specific (89%) and accurate (92%) than MRE without DWI 
(sensitivity 82%, specificity 74%, accuracy 79%), or DWI alone (sensitivity 
74%, specificity 63%, accuracy 66%) (42). 
 
Disease detection and activity assessment  
 
Aphthoid ulceration is an early macroscopic manifestation of active CD and is 
best appreciated by endoscopy.  Ulcer detection is challenging for MRI and 
highly dependent on both the morphology and depth of the ulcer and the 
technical quality of luminal distention. When visible, it may appear on T2 
weighted images as a small nidus of mural high signal intensity (SI) (due to 
crater filling with luminal contrast), surrounded by lower SI from bowel wall, 
and as a break in the line of mucosal enhancement on contrast enhanced T1 
weighed images (43). As disease severity and activity progress, the MRI 
manifestations become more apparent.  The MRI hallmarks of enteric CD are 
mural thickening and increased gadolinium enhancement (44) (Figure 1).  As 
discussed below, studies comparing MRI findings with endoscopic disease 
activity scores and/or histopathological inflammation have shown active 
disease is manifest on MRI by increasing mural thickness, deep ulceration, 
increased mural and perimural T2 signal (often appreciated best on fat-
saturated T2 images), avid mural contrast enhancement (especially in a 
layered pattern, frequently accompanied by increased mesenteric vascularity), 
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mural hyperintensity on high B value (>800) DWI, and increased loco-regional 
lymphadenopathy (14). Such features reflect histological hallmarks of active 
disease, namely mucosal ulceration, transmural inflammatory infiltrate, 
submucosal edema, and vasculopathy. A systematic review reported point 
estimates for per-patient sensitivity and specificity of MRE for diagnosis of CD 
as 78% (95% CI 67 to 84%) and 85% (95% CI 76 to 90%) respectively (45). 
 
MRI activity scores 
 
A major recent advance has been the development and validation of MRE 
based disease activity scores. These scores quantify disease activity, akin to 
endoscopic activity scoring systems such as the CD endoscopic index of 
severity (CDEIS). Components differ according to the individual score, but in 
general include radiologist scoring of parameters such as mural thickness, 
mural T2 signal intensity and avidity of contrast enhancement in comparison 
to an index tissue such as normal bowel wall or psoas muscle for example.  
Some also utilise signal intensity measurement via region of interest 
placement in the bowel wall. 
Such scores have undoubted utility in the research setting, but are 
implemented increasingly in routine clinical practice, both for phenotyping 
disease and, as discussed below, for therapeutic monitoring. 
 
While several scores are described sporadically in the literature, to date only 
two activity indices have been developed intentionally using an adequate 
independent external reference standard and thereafter validated successfully 
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in independent patient cohorts: the Magnetic Resonance Index of Activity 
(MaRIA) score and the Crohn’s disease MRE Index (CDMI) score (46, 47) . 
The MaRIA score was developed following a study in which the reference 
standard was the Crohn’s disease endoscopic index of severity (CDEIS) (46) 
and shows strong positive correlation with CDEIS when validated in 
independent cohorts (48).  The score is derived using the following formula: 
(MaRIA (segment) = 1.5 x wall thickness (mm) + 0.02 x Relative Contrast 
Enhancement [RCE} + 5 x oedema + 10 x ulceration)  
 
MaRIA requires evaluation for the presence of ulcers and increased mural T2 
signal (compared with psoas muscle) as a marker of mural oedema, along 
with measurement of mural thickness and relative contrast enhancement via 
placing regions of interest in the bowel wall. A threshold of ≥7 indicates active 
disease. The CDMI score was derived and validated via histological scoring of 
activity in surgical specimens and endoscopic biopsies (47), and relies 
predominantly on subjective assessments of the bowel and adjacent tissues 
compared to an internal reference such as normal bowel wall or a nearby 
vessel. In its simplest form, it requires grading of only bowel wall thickness 
and T2 signal scored from 1 to 3 in comparison to normal bowel (1.79 +1.34 
mural thickness score +0.94 mural T2 signal score) with a score ≥4.1 
denoting active CD. Diagnostic performance is improved slightly by the 
addition of scores for perimural T2 signal and avidity of contrast enhancement 
compared to a nearby vessel. CDMI has been expanded recently to create a 
global (as opposed to segmental) activity index by incorporating assessment 
of disease length and the presence of extra luminal complications such as 
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abscess and fistulae, creating the magnetic resonance enterography global 
Score (MEGS), which had a significant positive correlation (Spearman’s rank 
correlation= 0.458; P<0.001) with faecal calprotectin in a cohort of 71 patients 
(49). 
 
Both MaRIA and CDMI have high sensitivity (80-90%) for detecting active 
disease and are reproducible between radiologists (39,46–48). As discussed 
in following sections, they are also validated increasingly as biomarkers of 
therapeutic response. 
 
As noted previously, DWI also plays a role in activity assessment. An activity 
score incorporating Apparent Diffusion Co-efficient (ADC) measurement has 
recently been proposed (Clermont score: 1.646 × bowel thickness-1.321 × 
ADC+5.613 × edema+8.306 × ulceration+5.039) which is highly positively 
correlated with the MaRIA score (50). Whether ADC improves activity scores 
is however unclear presently given the well-documented problems of 
reducibility both within readers, and between different centers.  
 
Aberrant small bowel motility is a novel biomarker of disease activity that 
appears clinically useful. Several groups have showed negative correlation 
between software quantified bowel motility and disease activity (39,51,52). 
For example, Menys et al. showed bowel motility was negatively correlated 
(r=-0.52) with histopathological activity based on mucosal biopsies from 28 
patients (39). 
 
 15 
Penetrating disease 
 
As transmural inflammation worsens, ulcers deepen until they eventually 
penetrate the bowel wall completely. This produces an advancing sinus, 
which causes mesenteric inflammation culminating in a phlegmon, or an 
abscess if there is associated loculated infected fluid. Fistulation is caused by 
subsequent communication with an adjacent structure such as a bowel loop. 
Up to 15.5% of patients with CD have penetrating lesions at presentation and 
up to one-third will develop this phenotype during their lifetime. 
 
 On imaging an abscess appears as a well-defined, encapsulated fluid 
collection that does not conform to normal peritoneal or bowel anatomy. 
Abscess may also exert mass effect. The fluid component has high signal 
intensity (SI) on T2 and low SI on T1 with a variable thickness intermediate SI 
rim, which may enhance avidly. The associated fistula underlying the abscess 
is identified infrequently due limited spatial resolution on MRE (14,43) (Figure 
2). A phlegmon manifests as a region of often ill-defined increased mesenteric 
T2 SI adjacent to an inflamed bowel segment. The absence of a well-defined 
central fluid component distinguishes phlegmon from an abscess (14,43) 
(Figure 2).  
  
Fistulas appear as linear high T2 SI tracts joining the lumen of two structures. 
They are often best seen on post-contrast T1 sequences. Entero-enteric 
fistulas often present encircled by a series of matted loops (the so called 
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“starfish” sign), within which the individual tracts are often not visible discretely 
(14,43) (Figure 3). 
 
MRE is highly sensitive for detection of penetrating CD (53,54). Pooled data 
from studies comparing the accuracy of MRE for diagnosing fistulae (four 
studies) or abscess (three studies) suggested sensitivity/specificity of 
0.76/0.96 and 0.86/0.93 respectively against an endoscopic and/or surgical 
reference standard (45).  
 
 
 
Fibrotic disease 
 
Fibrosis is the sequelae of recurrent multiple cycles of treated inflammation 
followed by healing. It is often characterised by strictures that cause partial 
obstruction, although obstruction per se can also occur with active disease or 
with a mixed active/fibrotic picture. Indeed, it is rare for diseased bowel 
segments to be purely inflammatory or purely fibrotic: Both disease processes 
usually co-exist (Figure 4).  
  
Data describing the utility of MRE to detect and quantify fibrotic disease is 
sparse compared to that for inflammation. This mainly reflects the need for full 
thickness surgical specimens as a reference standard for mural fibrosis, as 
opposed to more easily obtained endoscopic activity scores, mucosal biopsies 
or clinical indices which are used to evaluate disease activity. In clinical 
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practice, reduced markers of disease activity (eg ulceration, increased mural 
T2 signal) usually infer that the diseased bowel is predominantly fibrotic, 
although this assumption has not been tested formally in large studies. Rimola 
et al. have recently demonstrated a significant association between grades of 
histological mural fibrosis and progressive enhancement at 7 minutes 
following gadolinium injection (Chi squared p<0.01) (55). Specifically, an 
enhancement gain of > 24% between 70 seconds and 7 minutes indicated 
bowel with severe fibrosis. Punwani et al. (56) reported that fibrosis is 
frequently associated with a layered enhancement pattern, and Zappa et al. 
(57) demonstrated a significant association with mural thickness (p = 0.0018) 
and more surprisingly, increased mural T2 signal intensity (p = 0.026), which 
is a known marker of disease activity. 
 
Magnetization transfer imaging is a novel technique that may be able to 
differentiate between fibrosis and inflammation (accepting that the two 
disease states often co-exist). Magnetization transfer imaging utilizes transfer 
of energy from protons in free water molecules to those associated with large 
molecules such as collagen, with fibrotic tissues demonstrating a high 
magnetization transfer effect (58). Dillman et al. reported significantly higher 
mean normalised bowel MTR in 10 rats with induced inflammation and fibrosis 
(0.58+/-0.08) when compared to 10 rats with induced inflammation only 
(0.45+/-0.05), (p=0.0003)  (58). Pazahr et al. assessed feasibility of MTR in 31 
CD patients undergoing 1.5T MRE. Patients were classified as having either 
acute/active inflammation, chronic/fibrostenosis, or a combination, by two 
independent radiologists using all acquired MRI sequences, with histological 
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findings available in 13 patients. MTR was increased significantly in fibrotic 
segments (35.3 ± 4.0 %, p < 0.0001) when compared to normal bowel (25.4 ± 
3.4 %) suggesting the technique may be both feasible and clinically useful in 
humans (59). 
 
MRI features of fibrosis reported in the literature are inconsistent, which 
probably reflects the frequent co-existence and variable proportions of both 
fibrosis and inflammation and which serves to complicate 
interpretation(55,57,58). Multi-site studies addressing this issue are underway 
currently. 
 
Monitoring therapeutic response 
 
The current aim of medical management for CD is to achieve mucosal healing 
where possible. It is widely accepted that MRE, with its ability to detect active 
disease, is a highly promising technique for disease monitoring (Figure 5) 
(14). As detailed above, MRE activity scores have been developed allowing 
more objective assessment of disease activity and subsequent treatment 
response (60).  
 
Several studies have formally investigated the ability of MRE to quantify 
therapeutic response to immunosuppressive therapy. Van Assche et al. (61) 
recruited 20 patients with active ileal CD (judged by CRP and contrast 
enhancement on MRE), initiating treatment with infliximab. Patients were 
assessed by MRE at baseline, 2 weeks and 6 months, the findings of which 
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were summarized by a numerical index of activity (MRE score of severity in 
Ileal Crohn's Disease (MICD) that combined transmural inflammation, 
extramural involvement and signs of obstruction. They found the MICD score 
improved by week 26 with particular improvement for inflammatory 
components. Ordas et al. (62) investigated 48 patients with active CD (judged 
by colonoscopic ulceration). Patients underwent MRE and colonoscopy at 
baseline and 12 weeks following treatment with corticosteroids or anti-TNF 
agents. Disease activity was assessed using the MaRIA score for MRE and 
the Crohn’s Disease Endoscopic Index of Severity (CDEIS) for colonoscopy. 
In patients with ulcer healing, mean CDEIS and MaRIA improved significantly 
at week 12 compared to those without ulcer healing: MRE detected ulcer 
healing with 90% accuracy.  
 
Prezzi et al. and Eder et al. both retrospectively evaluated the change in MRE 
activity scores (MEGS and Simple Enterographic Activity Score for Crohn’s 
Disease [SEAS-CD] respectively) in patients commencing anti-TNF therapy 
and demonstrated significant improvements of MRE scores in clinical 
responders, but not non responders (63,64).   
 
The clinical utility of quantified small bowel motility as a marker of therapeutic 
response has also been investigated recently. Specifically, Plumb et al 
evaluated 46 patients with active CD initiating anti-TNF therapy and found that 
anti-TNF responders had significantly greater improvements in motility than 
non-responders, and that these changes were observed as early as 12 weeks 
following initiation (65).  
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MRE also has a role for detecting early disease recurrence following surgical 
resection. Indeed, up to 70% of patients may require repeat surgery within 10 
years of their initial operation, a risk that can be reduced by timely introduction 
of medical therapy at the time of first recurrence (66,67). For example, Ojea et 
al. recruited 30 post resection patients who underwent both ileocolonoscopy 
and MRE. MRE revealed recurrence at the ileocolonic anastomosis correctly 
in 25 patients, with two false positives (68).  
 
Impact on management 
 
A central consideration regarding the clinical utility of any imaging technology 
is whether it directly influences patient care, and if so, how frequently. A small 
number of studies have addressed this topic for MRE. 
 
Hafeez et al. prospectively surveyed gastroenterologists’ diagnostic 
confidence, expectation of disease extent, and therapeutic plan before and 
after MRE in 51 patients with CD. MRE improved clinician diagnostic 
confidence significantly for disease presence and also changed therapeutic 
strategy in 61% (95% CI 47 to 74%) of cases (26). Cheriyan et al. and Litz et 
al. retrospectively analysed 57 and 28 CD patients respectively, 
demonstrating that MRE altered management in the majority of patients (82% 
and 60% respectively) (69,70). Garcia-Bosch et al. asked 4 clinicians to 
review case data for 100 patients with CD, including sequential addition of 
MRE and colonoscopic findings. They reported that clinicians more frequently 
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considered MRE alone as sufficient to plan patient management than 
colonoscopy (80% vs 34% respectively). Adding MRE findings to colonoscopy 
changed clinicians’ confidence grade for diagnosis of active disease, stenosis, 
fistula, and abscess in a higher proportion of patients than did adding 
ileocolonoscopy to MRE. Anti-TNF therapy was more frequently indicated 
based on MRE findings than those from colonoscopy, and MRE changed 
therapy in a greater proportion of cases than did colonoscopy (28% vs. 8% 
p<0.001) (71). 
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Small bowel Ultrasound  
 
Summary of Technique 
 
SBUS is a time-efficient, low-cost, radiation free and well-tolerated technique 
for bowel imaging, although specific expertise is variably available (14). Given 
these attributes, in many European countries, SBUS is commonly the first 
investigation performed on patients presenting with gastrointestinal 
symptoms. However utility as a first line investigation is not ubiquitous and 
uptake is much less in some parts of the world, for example in the United 
States of America.  As well as acting as a primary diagnostic tool, in many 
instances it can triage patients requiring more complex imaging.  
 
Technological advances in sonographic equipment have been pivotal in 
establishing sonography for assessment of CD.  Specifically the high spatial 
resolution of probe technology has facilitated detailed luminal and extra-
luminal assessment, as well as providing the ability to interrogate the bowel in 
real-time, setting it apart from other investigations including MRE (72–75). 
Nevertheless, it is well recognised that complete enteric examination, 
especially of deeper pelvic loops, may not always be possible by sonography 
and visualisation may be limited by luminal gas and body habitus (14). 
Sonographer variability is also often quoted by the literature as a weakness 
(76), although in reality the few studies performed specifically to investigate 
this aspect actually demonstrate moderate to good inter-observer agreement, 
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especially for mural thickness and substantial agreement for stenosing and 
penetrating disease (77–79). 
 
Patient preparation usually necessitates a 4-6 hour fast, which reduces 
luminal gas. No specific oral preparation is required for routine SBUS, and 
administration of IV contrast is rarely performed (72,73,80).  
 
Imaging is performed trans-abdominally with the patient supine. A 
combination of convex and linear array probes are employed in a systematic 
manner to cover the entire abdomen and pelvis, to ensure as far as possible 
that the whole bowel length has been interrogated. Lower frequency (3.5 to 5 
MHz) probes provide a panoramic view, particularly useful in obese patients 
and for evaluating the sigmoid/rectum via the window of a full bladder 
(72,74,75). Higher frequency (up to 18MHz) probes are essential for high 
resolution visualisation of bowel wall to reveal the well-described 5-layer 
pattern ((Figure 6) an inner hyperechoic layer represents the interface 
between the mucosa and the bowel lumen; a hypoechoic layer represents the 
deep mucosa; a hyperechoic layer, the submucosa; a hypoechoic layer the 
musclaris propria; and the final outer hyperechoic layer the serosa and the 
serosal fat), along with the underlying mural vascularization(72,74,75).  
Visualization quality depends on both operator and patient, the ileocaecal 
region, sigmoid, ascending, and descending colon are amenable to accurate 
visualisation. The ileum and jejunum can be difficult to assess in their entirety 
due to overlying bowel loops and a deep pelvic location, whereas visualisation 
of transverse colon is sometimes challenging because of its variable position. 
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Finally the rectum is often inaccessible due to its deep posterior pelvic 
location (72,74,75).  
 
Variations of basic SBUS technique include addition of intravenous contrast 
(Contrast enhanced US (CEUS)) and/or luminal distension via hyperosmolar 
luminal contrast (small intestine contrast US (SICUS), hydrosonography) 
(72,80,81). Both additions add to procedural complexity and time for 
radiologists, and to invasiveness for patients (72). 
 
CEUS facilitates real-time depiction of bowel perfusion following intravenous 
administration of microbubble contrast agent (80). For example, SonoVue® 
(Bracco SpA, Milano,Italy), which utilizes sulphur-hexafluoride microbubbles, 
with a mean diameter of 2.5microm (SF6) that have an average lifetime in the 
blood of 12 minutes (82). The interface between the sulphur-hexafluoride 
microbubbles and the aqueous medium is intensely hyperechoic thus 
increasing contrast between bloods and surrounding tissues. Once the 
operator has identified a potentially abnormal bowel loop, it may be 
interrogated further with CEUS. For this, the identified loop is imaged (using a 
specific contrast specific US mode such as Cadence Contrast Pulse 
Sequencing (CPS) or power modulation phase inversion (PMPI)) after 
intravenous injection of microbubble contrast. The transducer is kept 
stationary over the selected intestinal segment and consecutive multi-frame 
cine-clips are acquired during breath-holding and/or quiet free breathing (from 
0 to 60s) (80). Each cine-clip may be assessed both qualitatively and 
quantitatively using specific software packages. Qualitative assessment 
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includes identification of particular patterns of enhancement, such as 
submucosal or transmural enhancement that may reflect disease activity, with 
low or absent enhancement alternatively suggesting quiescent disease (80). 
Furthermore, software may generate time-intensity enhancement curves, 
providing semi-quantitative variables such as maximal enhancement, time-to-
peak enhancement, and the area under a time intensity curve (83). Such 
analysis is relatively onerous for widespread clinical adoption, but is of 
significant research interest.  
 
As discussed in more detail below, specific benefits for both CEUS and 
hydrosonography have been reported, including increased diagnostic 
accuracy, more confident identification of active disease (79,81,84), 
quantification of inflammation (85) and differentiation of inflammation from 
fibrosis (86,87). 
 
Disease detection and activity assessment  
 
Ulcer detection is cited infrequently in the sonographic literature. One study 
reviewed 545 ultrasound scans (of which 166 were from CD patients) and 
compared these with a variety of reference tests (BaF, colonoscopy, surgical 
specimens). They noted that focal disappearance of wall stratification 
positively correlated with the deep longitudinal ulcers in CD (88).  
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In addition to ulcer detection, there are multiple mural and peri-mural 
sonographic features that have been more commonly linked to CD activity. 
Akin to MRE, the most diagnostic of these is mural thickness (Figure 6).  
 
Several studies suggest that a mural thickness, of >3mm, is 88% sensitive 
and 93% specific for diagnosis of CD, with a higher threshold of >4mm being 
75% sensitive and 97% specific (73,89,90). A recent meta-analysis evaluated 
15 studies with a variety of thresholds to diagnose abnormal mural thickness 
(3-5 mm). Mean sensitivity was 88%, specificity 97% and the area under the 
SROC 0.94 (91).  
 
Another finding linked consistently to disease activity in the literature is 
increased mural blood flow on Doppler ultrasound (Figure 7). Specifically, 
increased Doppler signal within the bowel wall correlates positively with 
disease activity when judged by a combination of clinical and laboratory 
assessments across several studies (92–94). For example, Esteban et al. 
evaluated 79 patients and 35 healthy volunteers with colour Doppler 
ultrasound and compared findings with global physician assessment, which 
included CDAI, CRP, and other available imaging but blinded to US findings. 
Two radiologists reviewed all images in consensus, scoring any Doppler 
abnormality on a 3-point scale (where colour absence was scored 0 and clear 
identification of vessel paths in the inflamed gut walls scored 2). Comparison 
of gut wall vascularity found significant differences (p < 0.001) between active 
and inactive CD as well as between healthy volunteers and inactive CD 
patients (92). Spalinger et al. performed 119 Doppler US on 92 patients with 
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confirmed CD and compared findings with CDAI obtained the same week. 
Vessel density (defined as number of colour Doppler signals per square 
centimeter) was counted and classified subsequently as low (0 to 2 colour 
Doppler signals per cm2), moderate (3 to 5 colour Doppler signals per cm2), 
and high (>5 colour Doppler signals per cm2). Patients with active disease 
demonstrated higher proportions of moderate and high vessel density than 
those with quiescent disease (chi squared p<0.01) (94).  
 
Significantly increased splanchnic arterial flow has been noted in patients with 
CD but evidence of a relationship with disease activity has been conflicting. 
SMA Doppler is also cumbersome and time-consuming, limiting uptake in 
daily practice (95,96).  
 
Other less well-documented sonographic features associated with active 
disease include alterations in normally layered bowel wall echogenicity, and 
thickening and altered echogenicity of the mesentery, and mesenteric 
lymphadenopathy (72). Nylund et al. performed histological analysis of 
surgical specimens from 14 CD patients with CD, finding severe submucosal 
fibrosis in 40 of 55 segments that demonstrated a hyperechoic submucosa 
with diffuse hypoechoic elements (97). Maconi et al. correlated sonographic 
mesenteric hypertrophy with the degree of clinical or chemical activity in 185 
CD patients: Mesenteric fat hypertrophy was detected in 88 (47.6%), and 
these showed significantly higher CDAI (p=0.0001) and CRP (p=0.0001) 
compared to those without (98).  
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Ultrasound activity scores 
 
As opposed to the MRI literature, there is relatively little published data 
regarding sonographic scores of disease activity. A handful of studies have 
proposed scoring criteria, but only one has been validated. Calabrese et al. 
developed a quantitative index based on findings from hydrosonography, 
incorporating enteric (bowel wall thickness, lumen diameter, lesion length and 
number of lesions) and extra-enteric findings (fistula, mesenteric adipose 
tissue alteration, abscess and lymph nodes). Bowel segments were 
considered as hollow cylinders and standardised variations of the above 
variables were combined into a predictive model to generate a prognostic 
index with values ranging from 0 to 200 (Sonographic lesion index for CD 
(SLIC)), with scores subdivided into a 5 point severity scale (A-E). They used 
SLIC to assess 110 CD patients over 1-year. Median SLIC score was 
significantly higher in patients with CDAI>150 than those with CDAI <150 
(p<0.005), and scores were also higher in patients with raised CRP>5 mg/l 
compared to those with a normal CRP (p = 0.003). Furthermore, patients with 
higher SLIC (classified as group D/E) underwent surgery more frequently than 
those with lower SLIC (class A-C) (p<0.0001) (99).  
 
Individual studies have described scores able to predict the likelihood of 
surgery (100) and diagnose/grade endoscopic recurrence (101). Rigazio et al. 
performed US in 147 patients, of whom 48 required surgery within 30 days. 
Four US variables were independently associated with the need for surgery: 
Mural pattern; thickness; presence of fistulae/abscesses; stenosis). The 
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prognostic score correctly classified 84% of patients who ultimately underwent 
surgery (100). 
 
Penetrating disease  
 
SBUS is highly sensitive for penetrating disease: Early extramural extension 
manifests as discontinuous bowel wall margins with peripheral hypoechoic 
irregularities (75). A fissure may extend into the inflammatory conglomerate of 
mesenteric change and in turn produce cavities and more defined tracts that 
eventually communicate with other structures to form a fistula. Sinus tracts 
and fistulae manifest as tubular hypoechoic structures in the soft tissues 
immediately adjacent to inflamed loops (102). It is occasionally possible to 
observe bubbles of extraluminal gas within fistulae (75). Colour/power 
Doppler may further assist diagnosis of fistulae by detecting increased mural 
blood flow at the level of the fistula (103). 
 
Phlegmons appear as extraluminal, hypoechoic structures of variable 
morphology, with irregular, poorly defined margins while the typical 
sonographic feature of an abscess is that of a complex collection, partly fluid 
and primarily hypoechoic, also with poorly defined margins (Figure 8) . 
Echogenic bubbles of gas may be noted within an abscess (75).  
 
In very advanced penetrating disease, multiple adherent inflamed loops can 
present as an inflammatory conglomerate harbouring abscesses and fistulae. 
Sonographically, this appears as an irregular complex structure characterized 
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by heterogeneous hypoechoic and anechoic areas. Surrounding intestinal 
loops involved in the conglomerate are thickened and rigid, and sometimes 
lose their normal morphology (75). Doppler may assist in differentiating 
between abscesses and inflammatory masses as flow is only detected in the 
granulation tissue at the periphery of an abscess and is not seen centrally, as 
occurs with inflammatory masses (72). 
 
A systematic review of 3 studies investigating the accuracy of SBUS for CD 
abscess diagnosis (against a surgical reference standard) reported 
sensitivities ranging from 81% to 100%, with specificities ranging from 92% to 
94% (45). Additionally, US has great utility for percutaneous drainage, with 
success rates as high as 98% (104,105). SBUS has reportedly reasonable 
accuracy for diagnosis of intra-abdominal fistulae with four studies 
encompassing 99 fistulae reporting a sensitivity of 67% to 87%, with 
specificity between 90% and 100% (45).  
 
Despite high reported accuracy of SBUS for penetrating complications, in 
clinical practice it is widely recognized that diagnosis of abscess and fistula is 
influenced by their location. The ECCO-ESGAR consensus recommends that 
for suspected deep-seated fistulas, MRE and CT are preferable to SBUS (14) 
and from a clinical perspective if an intra-abdominal abscess or deep-seated 
fistula is suspected, SBUS is only recommended if other cross-sectional 
imaging modalities are unavailable or deemed unsuitable, for example to 
avoid radiation exposure in children. 
 
 31 
Fibrotic disease  
 
Few studies have addressed the issue of diagnosing fibrotic lesions using 
SBUS and those that do focus on intravenous contrast. Studies evaluating 
basic sonographic features via comparison with surgical specimens note that 
inflammatory and fibrotic disease frequently co-exist. This leads to difficulty 
with interpretation, a problem familiar to the MRE literature (86,106,107). For 
example, Maconi et al. scanned 43 patients undergoing surgery for ileal 
stenosis and reported three distinct patterns of the submucosa and 
muscularis mucosae (107): 1, a stratified pattern that was associated with a 
significantly higher degree of fibrosis; 2, a hypoechoic bowel wall pattern that 
had a higher prevalence of inflammatory intraepithelial neutrophil infiltrate; 3, 
a mixed echo pattern that showed a high degree of both intraepithelial–
interstitial neutrophil infiltrate and fibrosis (107). Ripolles et al. undertook pre-
operative contrast-enhanced US in 25 CD patients undergoing either small 
bowel or colonic resection. They assessed fibrostenosis on a 3 point score (0 
to 2) based upon the presence of stenosis, prestenotic dilatation, absence of 
colour Doppler signal, and low grade (<46%) contrast enhancement following 
microbubble contrast. They correctly classified 8 of 13 (62%) segments as 
fibrostenotic. The other 5 segments were judged inflammatory but of these, 4 
demonstrated combined features of both fibrosis and high-grade 
inflammation. The authors concluded that in bowel exhibiting both active 
disease and fibrosis, sonographic features of the former predominate (108). 
Quantitative evaluation of contrast-enhanced SBUS is not established in 
clinical practice, likely due to issues around repeatability and reproducibility 
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within and between centres, and examination cost and complexity. 
Nevertheless in one study using surgical resection specimens as a reference 
standard, a threshold of 65% for increased enhancement following US 
contrast administration demonstrated sensitivity of 93% (95% CI 66 to 99) and 
specificity of 69% (95% CI 39 to 90) for diagnosing inflammatory lesions as 
opposed to fibrostenotic lesions (86).  
 
Monitoring therapeutic response 
 
The relative simplicity and high patient acceptability of SBUS make it a very 
attractive option for monitoring disease response, and there is data supporting 
its utility in this role: Ruess et al. performed sequential SBUS assessments 
including colour Doppler in 17 patients with new or relapsed IBD (13 with CD), 
undergoing treatment with a variety of therapies. Bowel vascularity depicted 
by colour and power Doppler sonography was graded on a scale of 1 to 4 (1, 
no vascularity; 2, minimal vascularity or 1–5 pixels of color per centimeter; 3, 
moderate vascularity or >5 scattered foci of color or power signal per 
centimeter; 4, marked or severely increased vascularity with color and power 
Doppler signal present throughout the length of the involved segment, 
including discrete elongated vessels and areas of confluent vascularity). They 
demonstrated a decrease in both bowel wall thickness and Doppler grade at a 
mean interval of 25 days from initiation of medical therapy for CD  but as early 
as 6 days (93). Moreno et al. performed SBUS including Doppler flow grade 
(subjectively graded as absent [grade 0] increasing to marked vascularity 
[grade 3]) and colonoscopy (at baseline and after 1 year) in patients with 
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colonic CD initiating biological management. SBUS detected mucosal healing 
accurately when compared to an ileocolonoscopic reference standard (89.8% 
sensitivity for segmental analysis and 84.6% sensitivity for per-patient 
analysis). Specifically, mucosal healing was best detected by the presence of 
Doppler flow grade 0 or 1 (highest sensitivity 97.6%), while ongoing mural 
thickening had the greatest specificity (94.1%) for absence of mucosal 
healing; only one patient with a mural thickness <3 mm did not exhibit 
mucosal healing (109). Overall there were 15 false-negative segments (which 
only subtle findings of superficial ulcers and/or erythema on endoscopy), 8 of 
which were sigmoid or rectum, which as already noted, lie deep in the pelvis 
and are suboptimally assessed by SBUS as a result (109).  
 
Quaia et al. performed CEUS on 43 patients with known CD who were either 
starting medical management or had existing medication increased.  They 
found the area under the time intensity curve (following intravenous contrast) 
differed significantly (p < 0.05) between responders and non-responders (as 
defined by either clinical [CDAI], endoscopic [Rutgeert’s] or histology indices); 
no B-mode or Doppler features allowed differentiation between the two groups 
(83). Specifically, AUC for time intensity curves post intravenous microbubble 
contrast was 621.58 ± 374.53 units for responders compared to 1,199.64 ± 
386.39 for non-responders. Using their proposed (hydrosonography) 
ultrasound activity score detailed above, Calabrese et. Al. were able to 
demonstrate significant improvements in SLIC scores in responders (defined 
by steroid-free remission, with CDAI<150) compared to non-responders (from 
a cohort of 29 CD patients initiating anti-TNF treatment) (85).  
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A small number of studies have evaluated the sensitivity and specificity of 
SBUS for detection of post-surgical recurrence. Pallotta et al. performed 
hydrosonography and ileocolonoscopy in 58 post-surgical patients with CD. 
They found increasing mural thickness was associated with higher Rutgeert’s 
scores, and a threshold of anastomotic mural thickness of  >3.5mm identified 
all patients with endoscopic recurrence (101). Paredes et al. performed a 
similar study on 32 patients, and demonstrated that moderate to severe 
recurrence could be identified using mural thickness (threshold >5mm) and 
Doppler flow grades demonstrating moderate/marked vascularity with 
sensitivity and specificity of 80% and 75%, and 80% and 66.7% respectively. 
Employing a mural thickness of >3mm or the presence of any colour Doppler 
flow had sensitivities of 76.9% and 57.1%, and specificities of 87.0% and 40% 
respectively for any grade of recurrence (110). A more recent study by the 
same group investigated the potential diagnostic advantage of CEUS. They 
demonstrated improved accuracy for conventional parameters (mural 
thickness>3mm and colour Doppler positive) than previously, achieving 
89.8% sensitivity and 81.8% specificity (86).  However, adding contrast 
enhancement data, (specifically  >34.5% enhancement in the neoterminal 
ileum) improved diagnostic accuracy to 98% sensitivity and 81.8% specificity 
(86).  
 
Impact on management 
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Literature describing the impact of SBUS findings on individual patient 
trajectory is relatively sparse. Novak et al. evaluated 49 patients with CD 
prospectively (59% of which were asymptomatic), using clinical and 
serological tests as well as ultrasound. Two independent gastroenterologists 
made clinical decisions that were altered significantly after SBUS assessment 
in most patients (60% and 58%) (111). Interestingly, SBUS disclosed active 
disease in up to 52% of  patients asymptomatic on follow up (111,112). 
Wilkens et al. retrospectively reviewed 115 CD patients having 
comprehensive ultrasound and colonoscopy within 30 days of each other. 
Seventy-four patients (64%) had disease matched on the two tests but forty-
one (36%) patients demonstrated abnormal bowel on US alone, proximal to 
the reach of ileocolonoscopy (although of these only eight had disease 
confirmed by subsequent surgery: the remainder had no corroborative test). In 
29 (71%) of these patients, ultrasound demonstrated moderate or severe 
inflammation despite an endoscopic diagnosis of mild or no inflammation 
(113). This changed management in 22 (76%) of these patients (13 changes 
in medical therapy, 8 surgical referrals, 1 hospital admission), attributed to the 
SBUS (113). The emerging literature therefore supports a role for treatment 
monitoring using SBUS and also for follow up of asymptomatic patients given 
the high prevalence of asymptomatic (and thus untreated) inflammation.   
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Small bowel US vs. MR Enterography in CD 
It is clear that both MRE and SBUS are highly attractive modalities for 
diagnosis and follow up of CD. As discussed below, although the available 
literature suggests both SBUS and MRE have similar diagnostic accuracy in 
phenotyping CD, they are clearly very different techniques and each attracts 
its own advantages and disadvantages.  
 
The advantages of SBUS in general mirror those of conventional US ; it is 
cheap, equipment is readily-available and the technique is generally very well 
tolerated by patients. There is no absolute requirement for luminal distension 
with oral contrast or intravenous injection, adding to the relatively simplicity of 
the investigation.  Conversely MRE is relatively expensive, with more limited 
availability of equipment in many health care settings. Furthermore it may not 
be possible  in patients with claustrophobia, or those unable to breath hold 
reliably or lie still such as those with respiratory problems or young children.  
The technique necessitates good luminal distension and both IV spasmolytic 
injection and  IV gadolinium contrast agent use is routine.  
 
A common criticism of US is the potential to “miss” sections of the bowel due 
to anatomical location (for example deep pelvic loops and the rectum) or 
because of obscuration by bowel gas or overlying adipose tissue.  A 
technically complete MRI routinely visualizes the whole gut. Another often 
stated limitation of US is the potential for inter-observer variability due to both 
missed bowel loops and perceived subjectivity in image interpretation. 
However those studies which have specifically addressed observer variability 
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in general report very good agreement, at least for disease presence. For 
example in a study of 103 CD patients by two independent sonographers 
agreement was  near perfect (κ 0.91) (79). In a more detailed but smaller 
study of 29 patients, inter-observer variability for the presence of abscess was 
near perfect (κ 0.96), whilst for wall thickness (ICC 0.67), and presence of 
penetrating disease (κ 0.8) it was substantial. Agreement was however 
moderate for the length of disease (ICC 0.41), presence of stricture (κ 0.54) 
and grade of bowel wall Doppler signal (ICC 0.53) (77).  By comparison, many 
studies have evaluated inter-observer agreement in MRI, with results in 
general demonstrating a good to excellent inter-observer variability for the 
assessment of multiple features of CD (35,114).  
 
Another potential difference between the two techniques are the training 
requirements to gain competency. Few would disagree that radiologists 
require specific training when evaluating the small bowel for CD, although it is 
unclear whether this is greater for US then for MRI as is commonly supposed. 
There is in fact little data evaluating training requirements for competency in 
SBUS although learned bodies (for example European gastroenterologists) 
have produced detailed curriculums and advice  on learning strategies (115). 
With respect to MRE, one study investigating formal training with direct case-
by case feedback in 31 inexperienced readers concluded that experience of at 
least 100 cases was required to achieve the acceptable MRE activity grading 
accuracy of 75 % (116). 
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Regarding comparative diagnostic accuracy, four systematic reviews, 
including one meta-analysis, have evaluated the performance of imaging tests 
for both diagnosis and disease activity assessment (28,45,117,118). Most of 
the primary studies evaluated were single center and of relatively small 
numbers. Considerable heterogeneity in study design and reference 
standards were reported (28,45,117,118). The largest systematic review 
included 68 studies and compared CT, MRE and SBUS (45). For disease 
location the sensitivity of SBUS ranged from 75 to 93% versus 77 to 91% for 
MRE. Specificity ranged from 98 to 100% (SBUS) and 60 to 100% (MRE). 
Sensitivity and specificity for active disease for SBUS was 85% (range 75 to 
100%) and 91% (range 82 to 100%) respectively and for MRE were 80% 
(range 78 to 100%) and 82% (range 46% to 100%) respectively (45).  
 
Few  prospective studies have employed a direct diagnostic test comparison 
methodology that has been shown to reduce bias by assessing the same 
patients with multiple tests (119), combined with high quality reference 
standards. These are summarized in Table 2 (120–124). Given the relatively 
complexity of such studies and their onerous nature for patients, recruits are 
relatively few and studies are usually single centre.  Furthermore, studies 
differ in unit of analysis (per patient or per segment), primary endpoints 
(disease detection or disease activity), and employ a range of reference 
standards including colonoscopy, BaF, CT, or surgery. Accordingly, results 
are predictably heterogeneous. For example, Pascu et al. report per segment 
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sensitivity for disease as low as 38% for MR while, conversely, the figure for 
Potthaus was 97.5% (121,124).   
 
An answer may be provided by an ongoing multicenter, non-randomised, 
single-arm, prospective comparison study of SBUS and MRE in patients with 
newly diagnosed or established CD (the latter with suspected relapse): the 
METRIC study (ISRCTN03982913) (125). Recruitment is complete (334 
patients across 8 UK centers). The study will derive per patient and per 
segmental sensitivity and specificity for both disease and activity using a 
consensus panel reference standard after 6 months follow-up (126).  
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In conclusion, the diagnosis and follow-up of CD necessitates accurate 
assessment of disease presence, site, extent, activity and complications. 
Various diagnostic tests are available of which SB US and MRE are 
particularly attractive given they avoid ionizing radiation. Literature detailing 
diagnostic accuracy and clinical utility is expanding rapidly but large multisite 
study data remains elusive. Clinical practice is thus driven currently by expert 
consensus statements such as that produced jointly by ECCO and ESGAR 
(14). This recommends both MRE and USS as first line tests for management 
of CD but emphasise local expertise and resource availability in differing 
healthcare systems. Furthermore, they emphasize the need for future high 
quality research to address clinical uncertainty. This research should not only 
define the current role of imaging in clinical practice currently, but also 
examine future potential roles for activity assessment, therapeutic triage, 
follow up, and the potential to use novel imaging biomarkers as surrogate 
endpoints in therapeutic trials.  
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Legends 
 
Table 1. MRE protocol outlining (recommended) minimum and optional MRI 
sequences for both 1.5T and 3T scanners 
 
Table 2: Summary of studies in which both SBUS and MRE have been 
performed on patients to assess diagnostic performance (120–124)  
 
Figure 1: Active multifocal jejunal (J) and ileal (I) Crohn’s disease. Parts A,D-axial 
T2 weighted images demonstrating mural thickening and increased T2 signal in 
a jejunal (J) and ileal (I) loop. Parts B, E-axial fat saturated T1 weighted images 
after IV gadolinium injection demonstrates a layered  contrast enhancement 
pattern in both bowel loops. Parts C, F axial- diffusion weighted images (B1000) 
shows  hyperintensity  in the same loops. Part G- ADC map shows restricted 
diffusion in the ileal (I) loop. Note the adjacent fluid collection (c) in parts D-G 
 
 
Figure 2: Active terminal ileal CD with phlegmon and small abscess 
Part A-axial T2 weighted image. Part B axial contrast enhanced image. Part C 
axial diffusion weighted inage (B1000). The inflammed ileum (arrow) is 
thickened with increased mural T2 signal, hyper enhancement and resticted 
diffusion. The abscess (red circle) demonstrates ring enhancment (part B). 
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Figure 3: Penetrating CD with fistula involving multiple loops in a ‘starfish’ 
pattern. Part A-coronal T2 HASTE. Part B coronal fat saturated T2 HASTE. Part C 
coronal post contrast T1, with magnified view (part D). A small collection 
(arrow) is seen at the epicentre of the fistula which is involving the terminal 
ileum (TI), distal ileum (DI), sigmoid colon (SC) and bladder dome (B). Loculated 
ascites in the left iliac fossa is also noted (*). 
 
Figure 4: MRI and ultrasound images of a histologically proven mixed 
active/fibrotic stricture (arrow)  causing upstream bowel dilatation (*). Part A- 
axial TRUFISP image. The stricture  demonstrates relatively low signal intensity 
mural thickening. Part B-axial post contrast T1 VIBE. The stricture demonstrates 
homogenous contrast enhancement. Part C-axial  diffusion weighted image 
(b1000) demonstrates mildly increased mural signal in the sticture. Part D-
corresponding ultrasound images demonstrates well-defined mural thickening. 
Part E -Doppler imaging demonstrates some increased Doppler flow. 
 
Figure 5: MRI images demonstrating treatment response in an inflamed ileal 
loop.  Part A-coronal fat saturated T2 HASTE image before treatment with anti 
TNF alpha therapy. The inflamed ilea loop (arrows) demonstrates mural 
thickening and moderately increased mural signal.  Part B coronal fat saturated 
T2 HASTE image after 6 months of treatment. The ileal loop (arrows) 
demonstrates a reduction in mural thickening and mural signal indicating a 
reduction in inflammatory activity, consistent with treatment response 
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Figure 6: Ultrasound image demonstrating normal small bowel with 5-layer 
pattern (an inner hyperechoic layer represents the interface between the 
mucosa and the bowel lumen; a second hypoechoic layer represents the deep 
mucosa; a third hyperechoic layer, the submucosa; a fourth hypoechoic layer 
the musclaris propria; and the final outer hyperechoic layer the serosa and the 
serosal fat). 
 
Figure 7: Ultrasound images of active small bowel CD: Part A demonstrates 
mural thickening with an ill-defined echogenic and thickened submucosa (*). The 
mucosa is also subtly thickened (arrow). The mesenteric fat is hyperexpanded 
and stratified. Part B demonstrates focally increased Doppler flow 
 
Figure 8: Serial ultrasound images monitoring penetrating active CD in  a patient 
in the second-trimester of pregnancy.  Part A, demonstrates active terminal ileal 
(TI) disease with a large complex superficial collection (thin arrow). Parts B and 
C demonstrate a reduction in size of the superficial collection following 
superficial drainage, anti-biotic and immunosuppressive treatment. However an 
ileo-colic fistula is now visible (short arrow in part C). 
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Table 1  
 
Minimum (recommended) Coronal true FISP 
Buscopan 20mg IV 
Axial and Coronal non Fat Sat HASTE 
Coronal Fat Sat HASTE 
Coronal pre and post gadolinium T1 (60-70sec) 
Optional Axial Diffusion weighted imaging (DWI)  
 - b values 50 and 600 (may extend up to 
1000) 
Axial True FISP 
Axial Fat Sat HASTE 
Axial post gadolinium T1 
True FISP dynamic Motility 
Table 1. MRE protocol outlining (recommended) minimum and optional MRI 
sequences for both 1.5T and 3T scanners 
  
 64 
Table 2 
 
Study No. 
of 
pati
ents 
Presence/ 
Activity 
Analysis - 
Per 
Patient/ 
Segmenta
l 
Reference 
standard 
SBUS 
Sens/ 
Spec 
MRE  
Sens/
Spec 
Miao 30 Activity Patient Ileocolonoscopy, 
BaF, Surgery   
87%, 
100% 
87%, 
71% 
Pascu 37 Presence Segment Ileocolonoscopy 74%, 
97% 
38%, 
90% 
Martinez 30 Presence Segment Ileocolonoscopy, 
BaF, CT, Surgery 
91%, 
98% 
83%, 
97% 
Ziech 28 
(23 
IBD) 
Presence Patient Ileocolonoscopy 55%, 
100% 
57%, 
75-
100% 
Potthaust 46 Presence Segment None, Barium 
Enteroclysis, 
ileocolonoscopy, 
surgery 
76%, 
75% 
97.5%
, 
100% 
Table 2: Summary of studies in which both SBUS and MRE have been performed 
on patients to assess diagnostic performance (118–122)  
 
 
 
